Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity

Bottom line: The fight over blinding in psychedelic trials is missing the bigger picture: the psychological toll of disappointment.

A participant sits in a chair, eyes closed, hands clasped. They’ve just been told they’re receiving a placebo. The moment is charged with unspoken expectations—some hopeful, others deeply anxious. This is not just a clinical trial; it’s a psychological experiment in how people react to being told they’re not getting the active treatment.

The debate over blinding in psychedelic trials has been fierce. Researchers argue over whether participants can guess their treatment, whether that guessing skews results, and whether perfect blinding is even possible. But what if the real issue isn’t the blinding itself? What if the problem is the emotional response to the blinding—specifically, the disappointment that comes when you’re told you’re not getting the active treatment?

This is where the concept of lessebo enters the picture. A term first coined in the context of psychedelic research, lessebo refers to the negative placebo effect, where participants experience worsening symptoms or reduced benefit simply because they believe they’re receiving a placebo. But the study published in International Journal of Drug Policy argues that the focus on blinding is missing a key piece of the puzzle: the role of disappointment in shaping these outcomes. And the implications stretch far beyond the lab.

The Hidden Cost of Placebo: Why Disappointment Matters More Than Blinding

In most clinical trials, researchers assume that blinding is essential for accuracy. If participants know whether they’re receiving the active treatment or a placebo, their expectations might influence their reported symptoms. But the study challenges this assumption, suggesting that the problem isn’t just blinding—it’s what happens after the blinding is broken.

The authors point out that in many trials, especially those involving psychedelics, participants are often told they’re receiving a placebo. This creates a psychological divide: one group is hopeful, the other is anxious. But what if the real issue isn’t the blinding itself, but the emotional fallout from it? The study argues that disappointment—when participants realize they’re not getting the active treatment—can be just as powerful as expectation in shaping outcomes.

This is not a new idea. In the past, researchers have noted that placebo effects can be strong, but the lessebo effect is different. It’s not about the power of belief, but the pain of not being believed. When participants are told they’re getting a placebo, they may feel a sense of betrayal, especially if they were hoping for a real treatment. This emotional response can lead to a cascade of negative outcomes, from increased anxiety to worsened symptoms.

But the study goes further. It suggests that the problem isn’t just the expectation of receiving a placebo, but the management of disappointment. If participants are not prepared for the possibility of receiving a placebo, they may experience a stronger negative reaction than if they are given a realistic, structured explanation of what to expect. This means that the real issue in psychedelic trials isn’t whether blinding is perfect, but whether the trial is designed to account for the emotional consequences of blinding.

The Double Standard: Why Blinding is Overlooked in Mental Health Research

One of the most striking aspects of the study is its critique of the broader mental health research landscape. The authors argue that the intense focus on blinding in psychedelic trials reflects a double standard. In most other areas of mental health research, blinding is rarely assessed, and yet the same uncertainties that arise from imperfect blinding are often conflated with the limitations of patient-reported outcome measures.

This is a critical point. In many mental health trials, participants are asked to report their symptoms using standardized questionnaires. But these tools are often limited in their ability to capture the full complexity of mental health. At the same time, clinicians and researchers tend to view people living with mental disorders as unreliable reporters, despite the well-documented limitations of clinician-rated scales and the lack of robust biological markers for change.

The study suggests that this double standard is part of a larger issue: the tendency to prioritize blinding over the ethical and practical realities of conducting trials with vulnerable populations. If we assume that people with mental health conditions are unreliable, we may be missing out on valuable insights into how their expectations and emotions influence outcomes.

But the study also highlights a key insight: the maintenance of reasonable doubt about treatment allocation is what sustains the internal validity of placebo-controlled designs. In other words, the real goal isn’t perfect blinding—it’s the ability to maintain a balance between transparency and the need to protect participants from the emotional fallout of knowing they’re not getting the active treatment.

The Shift from Blinding to Preparation: A New Framework for Ethical Trials

If disappointment is the real issue, then the solution lies in how trials are designed to manage it. The study proposes a shift in focus from preserving blinding to preparing participants for the possibility of receiving a placebo. This means structuring the trial in a way that anticipates and addresses the emotional impact of blinding.

One key strategy is structured psychoeducation. By providing participants with a clear, realistic explanation of what to expect during the trial, researchers can help mitigate the negative effects of disappointment. This includes explaining the purpose of the placebo, the nature of the experience, and the potential for both positive and negative outcomes.

Another important element is strengthening the therapeutic alliance. If participants feel supported and understood throughout the trial, they may be less likely to experience disappointment or anxiety. This requires a more personalized approach to participant care, one that recognizes the emotional and psychological complexity of mental health treatment.

Finally, the study suggests that realistic preparation is essential. If participants are not prepared for the possibility of receiving a placebo, they may experience a stronger negative reaction. By designing trials that account for this possibility, researchers can create a more ethical and effective framework for evaluating psychedelic treatments.

Frequently Asked Questions

Q: What is lessebo?
A: Lessebo is a term used in psychedelic research to describe the negative placebo effect, where participants experience worsening symptoms or reduced benefit simply because they believe they’re receiving a placebo.

Q: Why is disappointment a bigger issue than blinding?
A: Because disappointment can have a strong psychological impact, especially when participants are told they’re not receiving the active treatment. This emotional response can shape outcomes in ways that blinding alone cannot account for.

Q: Does this mean blinding is unimportant?
A: No. The study acknowledges that blinding remains a critical component of clinical trials. However, it argues that the focus on blinding is missing a key piece of the puzzle: the role of disappointment in shaping outcomes.

Q: How can trials be designed to mitigate disappointment?
A: Through structured psychoeducation, strengthened therapeutic alliance, and realistic preparation. These strategies help participants understand what to expect and reduce the emotional impact of receiving a placebo.

Q: What does this mean for psychedelic research?
A: It suggests that the design of psychedelic trials needs to account for the full range of psychological and emotional responses to treatment allocation. This includes a more nuanced approach to blinding and a greater emphasis on participant preparation and support.

Sources

• ¶Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity
• ¶Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.